USA Intrauterine Devices (IUD’s) Market: By Method (Hormonal Intrauterine Device, Copper Intrauterine Device), By End User (Hospitals, Gynecology Clinics, Community Health Centers, and Others), and Country

USA Intrauterine Contraceptive Devices Market was valued at US$ 1,094.6 million in 2023 and is projected to reach US$ 1,379.5 million by 2029. In terms of sales revenue by method, the Hormonal Intrauterine Device segment accounted for more than 83% of revenue share and is projected to grow at 4.0% CAGR over the forecast period. Favourable regulatory environment such as approval of IUDs for younger women who have never given birth and also FDA approval for extended use of IUDs is creating a strong impetus in the IUDs industry. The hormonal Intrauterine Device (IUD) is a highly effective contraceptive method that is becoming more widely available. It has therapeutic and non-contraceptive benefits, including lighter bleeding and pain alleviation, as well as fewer side effects than other hormonal treatments. Hormonal IUDs are one of the most effective forms of reversible contraception available. They have a failure rate of less than 1%, making them highly reliable in preventing unintended pregnancies.

The Hospitals segment accounted for 43.8% revenue share in the USA Intrauterine Contraceptive Devices Market, and the market is projected to grow at 4.3% CAGR over the forecast period. Community Health Care Center segment accounted for 19.7% of revenue share in the USA Intrauterine Contraceptive Devices Market. Community health centers (CHCs) are an important source of care for many low-income and uninsured women of reproductive age. Over half of community health centers provide IUDs as part of the family planning services.

USA Intrauterine Devices Market Key Developments:

• On May 18, 2023, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced that its new next-generation, hormone-free, low-dose copper intrauterine device (IUD) showed positive results in a phase 3 study. In the trial, the Copper 175 mm2 IUD (VeraCept) was 99% effective in preventing pregnancy and well tolerated by the study participants.
• In June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences is conducting a phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety and tolerability. The trial expected to complete in June 2027.
• In the United States, the VeraCept Intrauterine Contraceptive is now being tested in a clinical trial. (Its use is restricted to investigational purposes under US federal law). VeraCept is a low-dose copper-releasing intrauterine device that prevents pregnancy without the need of hormones. In the United States, VeraCept is conducting Phase 3 Clinical Trials.
• In March 2021, A clinical study was initiated to check the Impact of Contraceptives on Cervico-Vaginal Mucosa (UMPALA) in the United States. UMPALA is a research study aims to examine the impact of four approved contraceptives on cervical and vaginal tissues, as well as blood factors.
• In addition, In 2020, Bayer and Direct Relief teamed up to launch the "We're for Her" campaign. The primary goal of this effort was to ensure that women in deprived areas of the United States have access to effective contraception.